Phase I, Open Label Dose Escalation Study to Evaluate Safety of iHIVARNA-01 in Chronically HIV-infected Patients

NCT02413645 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

21

Enrollment

OTHER

Sponsor class

Conditions

HIV-infection

Interventions

BIOLOGICAL: TriMix_100
BIOLOGICAL: TriMix_300
BIOLOGICAL: 600μg mRNA (300 μg HIV mRNA+300 μg TriMix mRNA)
BIOLOGICAL: 900μg mRNA (600 μg HIV mRNA+300 μg TriMix mRNA)
BIOLOGICAL: 1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA)

Sponsor

Judit Pich Martínez